On Thursday, Shake Shack Inc (NYSE:SHAK)’s shares declined -4.22% to $65.50.
Shake Shack Inc (NYSE:SHAK) Shake Shack® Westfield Stratford City is set to open on Wednesday May 20th 2015 at 10:30AM. This Shack will be located on “The Street” in the heart of the bustling Westfield Stratford City shopping centre.
Shake Shack is a critically acclaimed, modern day “roadside” burger stand known for its 100% all-natural, antibiotic-free Angus beef burgers (no hormones added ever), griddled flat-top dogs, fresh-made frozen custard, crispy crinkle cut fries and more. A fun and lively community gathering place with widespread appeal, Shake Shack has earned a cult-like following around the world.
Shake Shack Inc. owns, operates, and licenses Shake Shack restaurants (Shacks) in the United States, the District of Columbia, North America, Europe, and Asia. Shacks offers hamburgers, hot dogs, crinkle-cut fries, shakes, frozen custard, beer, and wine. As of December 31, 2014, it had 63 Shacks, counting 31 domestic company-operated Shacks, 5 domestic licensed Shacks, and 27 international licensed Shacks.
Abraxas Petroleum Corp (NASDAQ:AXAS)’s shares dropped -4.00% to $3.12.
Abraxas Petroleum Corp (AXAS) stated financial and operating results for the three months ended March 31, 2015.
Financial and Operating Results for the Three Months Ended March 31, 2015
The three months ended March 31, 2015 resulted in:
- Production of 593 MBoe (6,590 Boepd)
- Revenue of $22.3 million inclusive of realized hedge settlements
- Adjusted EBITDA(a)of $13.2 million inclusive of Raven Drilling
- Adjusted discretionary cash flow(a)of $12.5 million inclusive of Raven Drilling
- Net loss of $0.7 million, or $0.01 per share
Abraxas Petroleum Corporation, an independent energy company, engages in the acquisition, exploitation, development, and production of oil and gas properties in the United States.
Adjusted net loss, not taking into account certain non-cash items, for the three months ended March 31, 2015 was $1.2 million, or $0.01 per share, contrast to an adjusted net income, not taking into account certain non-cash items, of $6.7 million or $0.07 per share for the three months ended March 31, 2014. For the three months ended March 31, 2015 and 2014, adjusted net income (loss) excludes the unrealized gain (loss) on derivative contracts of $1.2 million and of $(0.9) million, respectively. Comprised of in adjusted net income (loss) is the net income for the quarters ended March 31, 2015 and March 31, 2014 from our partner, Raven Drilling, LLC of $0.7 million and $0.6 million, respectively.
At the end of Thursday’s trade, Northern Oil & Gas, Inc. (NYSEMKT:NOG)‘s shares dipped -3.90% to $6.65.
Northern Oil & Gas, Inc. (NYSEMKT:NOG) declared that it priced its private offering to eligible purchasers of $200 million in aggregate principal amount of its 8.000% senior notes due 2020 (the “notes”) at an offering price equal to 95.000% of par. The notes will be Northern Oil’s general unsecured obligations. Northern Oil intends to use the net proceeds of about $184.9 million, after deducting initial purchasers’ discounts and offering expenses, to repay borrowings outstanding under its revolving credit facility and for other general corporate purposes. The offering is predictable to close on May 18, 2015, subject to the satisfaction of customary closing conditions.
Northern Oil and Gas, Inc., an independent energy company, engages in the acquisition, exploration, development, and production of oil and natural gas properties in the United States.
Foundation Medicine Inc (NASDAQ:FMI), ended its Thursday’s trading session with -3.80% loss, and closed at $37.68.
Foundation Medicine Inc (NASDAQ:FMI) declared new data demonstrating that its comprehensive genomic profiling assay, FoundationOne®, identified a high frequency of clinically relevant genomic alterations in pediatric gliomas that informed treatment decisions and, in some cases, resulted in promising outcomes in a notoriously challenging disease. These findings were presented in a poster titled “Comprehensive genomic profiling (CGP) of pediatric gliomas reveals a high frequency of clinically relevant genomic alterations (CRGA) to inform treatment decisions” by Zachary Chalmers, research associate at Foundation Medicine, at the 3rd Biennial Pediatric Neuro-Oncology Basic and Translational Research Conference in San Diego.
Foundation Medicine, Inc. provides various molecular information products in the United States. Its molecular information platform comprises proprietary methods and algorithms to analyze specimens across various types of cancer, in addition to for incorporating that information into clinical care; and offers genomic information about each patient’s individual cancer, enabling physicians to optimize treatments in clinical practice and biopharmaceutical companies to develop targeted oncology therapies.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
